In line with this hypothesis, postnatal treatment with the Glp1 receptor agonist Exendin 4 in animals that suffered from experimental IUGR reduced the adverse metabolic phenotypes of fetal IUGR in adulthood (10, 14). Here, GLP1R is linked to fetal growth restriction.